Literature DB >> 30269440

Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis.

Amandeep K Dhillon1,2,3, Martin Kummen1,2,3, Marius Trøseid2,3,4, Sissel Åkra5, Evaggelia Liaskou6, Bjørn Moum2,7, Mette Vesterhus1,8,9, Tom H Karlsen1,2,3,10, Ingebjørg Seljeflot2,5, Johannes R Hov1,2,3,10.   

Abstract

BACKGROUND & AIMS: One important hypothesis in primary sclerosing cholangitis pathophysiology suggests that bacterial products from an inflamed leaky gut lead to biliary inflammation. We aimed to investigate whether circulating markers of bacterial translocation were associated with survival in a Norwegian primary sclerosing cholangitis cohort.
METHODS: Serum levels of zonulin, intestinal fatty acid binding protein, soluble CD14, lipopolysaccharide and lipopolysaccharide-binding protein were measured in 166 primary sclerosing cholangitis patients and 100 healthy controls.
RESULTS: Lipopolysaccharide-binding protein and soluble CD14 were elevated in primary sclerosing cholangitis compared with healthy controls (median 13 662 vs 12 339 ng/mL, P = 0.010 and 1657 vs 1196 ng/mL, P < 0.001, respectively). High soluble CD14 and lipopolysaccharide-binding protein (values >optimal cut-off using receiver operating characteristics) were associated with reduced liver transplantation-free survival (P < 0.001 and P = 0.005, respectively). The concentration of soluble CD14 was higher in patients with hepatobiliary cancer compared to other primary sclerosing cholangitis patients and healthy controls. Zonulin was lower in primary sclerosing cholangitis than controls, but when excluding primary sclerosing cholangitis patients with increased prothrombin time zonulin concentrations were similar in primary sclerosing cholangitis and healthy controls. Concomitant inflammatory bowel disease did not influence the results, while inflammatory bowel disease patients without primary sclerosing cholangitis (n = 40) had lower concentration of soluble CD14. In multivariable Cox regression, high soluble CD14 and high lipopolysaccharide-binding protein were associated with transplantation-free survival, independent from Mayo risk score (HR: 2.26 [95% CI: 1.15-4.43], P = 0.018 and HR: 2.00 [95% CI: 1.17-3.43], P = 0.011, respectively).
CONCLUSIONS: Primary sclerosing cholangitis patients show increased levels of circulating markers of bacterial translocation. High levels are associated with poor prognosis measured by transplantation-free survival, indicating that ongoing gut leakage could have clinical impact in primary sclerosing cholangitis.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  LBP; LPS; gut leakage markers; primary sclerosing cholangitis; sCD14; zonulin

Mesh:

Substances:

Year:  2018        PMID: 30269440     DOI: 10.1111/liv.13979

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  12 in total

Review 1.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

2.  Hepatic Macrophage activation and the LPS pathway in patients with different degrees of severity and histopathological patterns of drug induced liver injury.

Authors:  Hui-Juan Du; Su-Xian Zhao; Wen Zhao; Na Fu; Wen-Cong Li; Xiao-Jie Qin; Yu-Guo Zhang; Yue-Min Nan; Jing-Min Zhao
Journal:  Histol Histopathol       Date:  2021-04-15       Impact factor: 2.303

Review 3.  Gut microbiome in primary sclerosing cholangitis: A review.

Authors:  Rebecca Little; Eytan Wine; Binita M Kamath; Anne M Griffiths; Amanda Ricciuto
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

4.  Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis.

Authors:  Lars Bossen; Mette Vesterhus; Johannes R Hov; Martti Färkkilä; William M Rosenberg; Holger J Møller; Kirsten M Boberg; Tom H Karlsen; Henning Grønbæk
Journal:  Clin Transl Gastroenterol       Date:  2021-03-01       Impact factor: 4.396

Review 5.  The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective.

Authors:  Kevin De Muynck; Bart Vanderborght; Hans Van Vlierberghe; Lindsey Devisscher
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

Review 6.  Gut-Liver Axis and Inflammasome Activation in Cholangiocyte Pathophysiology.

Authors:  Luca Maroni; Elisabetta Ninfole; Claudio Pinto; Antonio Benedetti; Marco Marzioni
Journal:  Cells       Date:  2020-03-17       Impact factor: 6.600

Review 7.  Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities.

Authors:  Mette Vesterhus; Tom Hemming Karlsen
Journal:  J Gastroenterol       Date:  2020-03-28       Impact factor: 7.527

Review 8.  The Gut-Liver Axis in Cholestatic Liver Diseases.

Authors:  Andreas Blesl; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-03-21       Impact factor: 5.717

Review 9.  TLR4 signaling in the development of colitis-associated cancer and its possible interplay with microRNA-155.

Authors:  Jie Guo; Mengfan Liao; Jun Wang
Journal:  Cell Commun Signal       Date:  2021-09-03       Impact factor: 5.712

10.  Intestinal barrier dysfunction plays an integral role in arthritis pathology and can be targeted to ameliorate disease.

Authors:  Diana E Matei; Madhvi Menon; Dagmar G Alber; Andrew M Smith; Bahman Nedjat-Shokouhi; Alessio Fasano; Laura Magill; Amanda Duhlin; Samuel Bitoun; Aude Gleizes; Salima Hacein-Bey-Abina; Jessica J Manson; Elizabeth C Rosser; Nigel Klein; Paul A Blair; Claudia Mauri
Journal:  Med (N Y)       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.